Antibodies to the HLA-A2 antigen prime neutrophils and serve as the second event in an in vitro model of transfusion-related acute lung injury

Vox Sanguinis

Volumn 107, Issue 1, 2014, Pages 76-82

  Silliman, C C ^a,b,c   Bercovitz, R S ^a,b   Khan, S Y ^a,b   Kelher, M R ^c   Lasarre, M ^a   Land, K J ^d   Sowemimo Coker, S ^e  

^a Bonfils Blood Center   (United States)

^b University of Colorado Denver and Children s Hospital Colorado   (United States)

^c UNIVERSITY OF COLORADO   (United States)

^d Blood Systems Incorporated   (United States)

^e HAEMONETICS CORPORATION   (United States)

Author keywords

Cytotoxicity; Homozygous HLA A2; Pulmonary endothelium

Indexed keywords

HLA A2 ANTIBODY; HLA ANTIBODY; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG; HLA A2 ANTIGEN;

ANTIGEN BINDING; ARTICLE; CONTROLLED STUDY; CROSS PRESENTATION; CYTOTOXICITY; HETEROZYGOTE; HOMOZYGOTE; HUMAN; HUMAN CELL; IN VITRO STUDY; NEUTROPHIL; NULL ALLELE; PRIORITY JOURNAL; TRANSFUSION RELATED ACUTE LUNG INJURY; ACUTE LUNG INJURY; ANALYSIS OF VARIANCE; BIOLOGICAL MODEL; BLOOD TRANSFUSION; IMMUNOLOGY;

ACUTE LUNG INJURY; ANALYSIS OF VARIANCE; ANTIBODIES, MONOCLONAL; BLOOD TRANSFUSION; HLA-A2 ANTIGEN; HUMANS; MODELS, IMMUNOLOGICAL; NEUTROPHILS;

EID: 84902302886     PISSN: 00429007     EISSN: 14230410     Source Type: Journal    
DOI: 10.1111/vox.12129     Document Type: Article

References (48)

1. Chapman CE, Stainsby D, Jones H, et al.: Ten years of hemovigilance reports of transfusion-related acute lung injury in the United Kingdom and the impact of preferential use of male donor plasma. Transfusion 2009; 49:440-452
2. Eder AF, Herron RM Jr, Strupp A, et al.: Effective reduction of transfusion-related acute lung injury risk with male-predominant plasma strategy in the American Red Cross (2006-2008). Transfusion 2010; 50:1732-1742
3. Eder AF, Dy BA, Perez JM, et al.: The residual risk of transfusion-related acute lung injury at the American Red Cross (2008-2011): limitations of a predominantly male-donor plasma mitigation strategy. Transfusion 2013; 53:1442-1449
4. Hendrickson JE, Hillyer CD: Noninfectious serious hazards of transfusion. Anesth Analg 2009; 108:759-769
5. Holness L, Knippen MA, Simmons L, et al.: Fatalities caused by TRALI. Transfus Med Rev 2004; 18:184-188
6. Popovsky MA, Moore SB: Diagnostic and pathogenetic considerations in transfusion-related acute lung injury. Transfusion 1985; 25:573-577
7. Popovsky MA: Transfusion-related acute lung injury; Popovsky MA (ed): Transfusion Reactions, 1st edn. Bethesda, MD, American Association of Blood Banks Press, 1996: 167-183.
8. Curtis BR, Cox NJ, Sullivan MJ, et al.: The neutrophil alloantigen HNA-3a (5b) is located on choline transporter-like protein 2 and appears to be encoded by an R>Q154 amino acid substitution. Blood 2010; 115:2073-2076
9. Gajic O, Rana R, Winters JL, et al.: Transfusion related acute lung injury in the critically Ill: prospective nested case-control study. Am J Respir Crit Care Med 2007; 176:886-891
10. Greinacher A, Wesche J, Hammer E, et al.: Characterization of the human neutrophil alloantigen-3a. Nat Med 2010; 16:45-48
11. Kopko PM, Popovsky MA, MacKenzie MR, et al.: HLA class II antibodies in transfusion-related acute lung injury. Transfusion 2001; 41:1244-1248
12. Kopko PM, Marshall CS, MacKenzie MR, et al.: Transfusion-related acute lung injury: report of a clinical look-back investigation. JAMA 2002; 287:1968-1971
13. Seeger W, Schneider U, Kreusler B, et al.: Reproduction of transfusion-related acute lung injury in an ex vivo lung model. Blood 1990; 76:1438-1444
14. Van Buren NL, Stroncek DF, Clay ME, et al.: Transfusion-related acute lung injury caused by an NB2 granulocyte- specific antibody in a patient with thrombotic thrombocytopenic purpura. Transfusion 1990; 30:42-45
15. Varela M, Mas A, Nogues N, et al.: TRALI associated with HLA class II antibodies. Transfusion 2002; 42:1102
16. Win N, Brown C, Navarrete C: TRALI associated with HLA class II antibodies. Transfusion 2003; 43:545-546
17. Yomtovian R, Kline W, Press C, et al.: Severe pulmonary hypersensitivity associated with passive transfusion of a neutrophil-specific antibody. Lancet 1984; 1:244-246
18. Silliman CC, Curtis BR, Kopko PM, et al.: Donor antibodies to HNA-3a implicated in TRALI reactions prime neutrophils and cause PMN-mediated damage to human pulmonary microvascular endothelial cells in a two-event in vitro model. Blood 2007; 109:1752-1755
19. Kelher MR, Masuno T, Moore EE, et al.: Plasma from stored packed red blood cells and MHC class I antibodies causes acute lung injury in a 2-event in vivo rat model. Blood 2009; 113:2079-2087
20. Looney MR, Su X, Van Ziffle JA, et al.: Neutrophils and their Fc gamma receptors are essential in a mouse model of transfusion-related acute lung injury. J Clin Invest 2006; 116:1615-1623
21. Sachs UJ, Hattar K, Weissmann N, et al.: Antibody-induced neutrophil activation as a trigger for transfusion-related acute lung injury in an ex vivo rat lung model. Blood 2006; 107:1217-1219
22. Silliman CC, Moore EE, Kelher MR, et al.: Identification of lipids that accumulate during the routine storage of prestorage leukoreduced red blood cells and cause acute lung injury. Transfusion 2011; 51:2549-2554
23. Bux J, Becker F, Seeger W, et al.: Transfusion-related acute lung injury due to HLA-A2-specific antibodies in recipient and NB1-specific antibodies in donor blood. Br J Haematol 1996; 93:707-713
24. Leach M, Vora AJ, Jones DA, et al.: Transfusion-related acute lung injury (TRALI) following autologous stem cell transplant for relapsed acute myeloid leukaemia: a case report and review of the literature. Transfus Med 1998; 8:333-337
25. Win N, Montgomery J, Sage D, et al.: Recurrent transfusion-related acute lung injury. Transfusion 2001; 41:1421-1425
26. Silliman CC, Clay KL, Thurman GW, et al.: Partial characterization of lipids that develop during the routine storage of blood and prime the neutrophil NADPH oxidase. J Lab Clin Med 1994; 124:684-694
27. Fuggle SV, Martin S: Tools for human leukocyte antigen antibody detection and their application to transplanting sensitized patients. Transplantation 2008; 86:384-390
28. Wyman TH, Bjornsen AJ, Elzi DJ, et al.: A two-insult in vitro model of PMN-mediated pulmonary endothelial damage: requirements for adherence and chemokine release. Am J Physiol Cell Physiol 2002; 283:C1592-C1603
29. Kelher MR, Silliman CC: Antibodies specific for MHC class II antigens cause TRALI directly in a two-event in vivo model: ed 120, 2012, p. 845.
30. Khan SY, Kelher MR, Heal JM, et al.: Soluble CD40 ligand accumulates in stored blood components, primes neutrophils through CD40, and is a potential cofactor in the development of transfusion-related acute lung injury. Blood 2006; 108:2455-2462
31. Silliman CC, Fung YL, Ball JB, et al.: Transfusion-related acute lung injury (TRALI): current concepts and misconceptions. Blood Rev 2009; 23:245-255
32. Creamer P, Edmonds J, Sullivan J, et al.: Measurement of HLA class I expression in ankylosing spondylitis. Ann Rheum Dis 1992; 51:1138-1142
33. Lansdorp PM, Oosterhof F, Astaldi GC, et al.: Detection of HLA antigens on blood platelets and lymphocytes by means of monoclonal antibodies in an ELISA technique. Tissue Antigens 1982; 19:11-19
34. Lepage V, Degos L, Dausset J: A "natural" anti-HLA-A2 antibody reacting with homozygous cells. Tissue Antigens 1976; 8:139-142
35. Zareparsi S, James DM, Kaye JA, et al.: HLA-A2 homozygosity but not heterozygosity is associated with Alzheimer disease. Neurology 2002; 58:973-975
36. Benson AB, Austin GL, Berg M, et al.: Transfusion-related acute lung injury in ICU patients admitted with gastrointestinal bleeding. Intensive Care Med 2010; 36:1710-1717
37. Davoren A, Curtis BR, Shulman IA, et al.: TRALI due to granulocyte-agglutinating human neutrophil antigen-3a (5b) alloantibodies in donor plasma: a report of 2 fatalities. Transfusion 2003; 43:641-645
38. Hashimoto S, Nakajima F, Kamada H, et al.: Relationship of donor HLA antibody strength to the development of transfusion-related acute lung injury. Transfusion 2010; 50:2582-2591
39. Kao GS, Wood IG, Dorfman DM, et al.: Investigations into the role of anti-HLA class II antibodies in TRALI. Transfusion 2003; 43:185-191
40. Middelburg RA, van Stein D, Briet E, et al.: The role of donor antibodies in the pathogenesis of transfusion-related acute lung injury: a systematic review. Transfusion 2008; 48:2167-2176
41. Middelburg RA, van Stein D, Zupanska B, et al.: Female donors and transfusion-related acute lung injury: a case-referent study from the International TRALI Unisex Research Group. Transfusion 2010; 50:2447-2454
42. Sanchez R, Bacchetti P, Toy P: Transfusion-related acute lung injury: a case-control pilot study of risk factors. Am J Clin Pathol 2007; 128:128-134
43. Silliman CC, Paterson AJ, Dickey WO, et al.: The association of biologically active lipids with the development of transfusion-related acute lung injury: a retrospective study. Transfusion 1997; 37:719-726
44. Silliman CC, Boshkov LK, Mehdizadehkashi Z, et al.: Transfusion-related acute lung injury: epidemiology and a prospective analysis of etiologic factors. Blood 2003; 101:454-462
45. Vlaar AP, Binnekade JM, Prins D, et al.: Risk factors and outcome of transfusion-related acute lung injury in the critically ill: a nested case-control study. Crit Care Med 2010; 38:771-778
46. Vlaar AP, Hofstra JJ, Determann RM, et al.: Transfusion-related acute lung injury in cardiac surgery patients is characterized by pulmonary inflammation and coagulopathy: a prospective nested case-control study. Crit Care Med 2012; 40:2813-2820
47. Wallis JP, Lubenko A, Wells AW, et al.: Single hospital experience of TRALI. Transfusion 2003; 43:1053-1059
48. Toy P, Hollis-Perry KM, Jun J, et al.: Recipients of blood from a donor with multiple HLA antibodies: a lookback study of transfusion-related acute lung injury. Transfusion 2004; 44:1683-1688